WO2018051325A1 - Stable pharmaceutical foam - Google Patents
Stable pharmaceutical foam Download PDFInfo
- Publication number
- WO2018051325A1 WO2018051325A1 PCT/IL2017/000007 IL2017000007W WO2018051325A1 WO 2018051325 A1 WO2018051325 A1 WO 2018051325A1 IL 2017000007 W IL2017000007 W IL 2017000007W WO 2018051325 A1 WO2018051325 A1 WO 2018051325A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- full
- peptone
- protein
- foam
- solution
- Prior art date
Links
- 239000008255 pharmaceutical foam Substances 0.000 title claims abstract description 52
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 181
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 181
- 239000001888 Peptone Substances 0.000 claims abstract description 160
- 108010080698 Peptones Proteins 0.000 claims abstract description 160
- 235000019319 peptone Nutrition 0.000 claims abstract description 160
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 claims abstract description 65
- 230000007071 enzymatic hydrolysis Effects 0.000 claims abstract description 61
- 239000000203 mixture Substances 0.000 claims abstract description 59
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 52
- 238000000034 method Methods 0.000 claims abstract description 47
- 239000000413 hydrolysate Substances 0.000 claims abstract description 18
- 238000002360 preparation method Methods 0.000 claims abstract description 8
- 235000018102 proteins Nutrition 0.000 claims description 179
- 239000006260 foam Substances 0.000 claims description 178
- 239000000243 solution Substances 0.000 claims description 76
- 108010010803 Gelatin Proteins 0.000 claims description 68
- 239000008273 gelatin Substances 0.000 claims description 68
- 229920000159 gelatin Polymers 0.000 claims description 68
- 235000019322 gelatine Nutrition 0.000 claims description 68
- 235000011852 gelatine desserts Nutrition 0.000 claims description 68
- 108010009736 Protein Hydrolysates Proteins 0.000 claims description 45
- 239000003531 protein hydrolysate Substances 0.000 claims description 45
- 238000005187 foaming Methods 0.000 claims description 32
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 30
- 108090000190 Thrombin Proteins 0.000 claims description 25
- 229960004072 thrombin Drugs 0.000 claims description 25
- 239000005018 casein Substances 0.000 claims description 24
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims description 24
- 235000021240 caseins Nutrition 0.000 claims description 24
- 108010049003 Fibrinogen Proteins 0.000 claims description 22
- 102000008946 Fibrinogen Human genes 0.000 claims description 22
- 229940012952 fibrinogen Drugs 0.000 claims description 22
- 239000007864 aqueous solution Substances 0.000 claims description 21
- 230000007062 hydrolysis Effects 0.000 claims description 18
- 238000006460 hydrolysis reaction Methods 0.000 claims description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- 229910001868 water Inorganic materials 0.000 claims description 13
- 102000004190 Enzymes Human genes 0.000 claims description 12
- 108090000790 Enzymes Proteins 0.000 claims description 12
- 229940088598 enzyme Drugs 0.000 claims description 12
- 238000007789 sealing Methods 0.000 claims description 9
- 230000029663 wound healing Effects 0.000 claims description 6
- 102000009123 Fibrin Human genes 0.000 claims description 5
- 108010073385 Fibrin Proteins 0.000 claims description 5
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims description 5
- 229950003499 fibrin Drugs 0.000 claims description 5
- 108091005502 Aspartic proteases Proteins 0.000 claims description 4
- 102000035101 Aspartic proteases Human genes 0.000 claims description 4
- 108010005843 Cysteine Proteases Proteins 0.000 claims description 4
- 102000005927 Cysteine Proteases Human genes 0.000 claims description 4
- 108091005503 Glutamic proteases Proteins 0.000 claims description 4
- 108010006035 Metalloproteases Proteins 0.000 claims description 4
- 102000005741 Metalloproteases Human genes 0.000 claims description 4
- 102000035195 Peptidases Human genes 0.000 claims description 4
- 108091005804 Peptidases Proteins 0.000 claims description 4
- 239000004365 Protease Substances 0.000 claims description 4
- 108010022999 Serine Proteases Proteins 0.000 claims description 4
- 102000012479 Serine Proteases Human genes 0.000 claims description 4
- 108091005501 Threonine proteases Proteins 0.000 claims description 4
- 102000035100 Threonine proteases Human genes 0.000 claims description 4
- 230000023597 hemostasis Effects 0.000 claims description 4
- 230000003301 hydrolyzing effect Effects 0.000 claims description 4
- 230000000415 inactivating effect Effects 0.000 claims description 2
- 238000007906 compression Methods 0.000 description 29
- 230000006835 compression Effects 0.000 description 29
- 239000007788 liquid Substances 0.000 description 28
- 108010076119 Caseins Proteins 0.000 description 22
- AIUDWMLXCFRVDR-UHFFFAOYSA-N dimethyl 2-(3-ethyl-3-methylpentyl)propanedioate Chemical class CCC(C)(CC)CCC(C(=O)OC)C(=O)OC AIUDWMLXCFRVDR-UHFFFAOYSA-N 0.000 description 22
- 229940066779 peptones Drugs 0.000 description 22
- 210000001519 tissue Anatomy 0.000 description 12
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 11
- 150000001413 amino acids Chemical class 0.000 description 11
- 229940098773 bovine serum albumin Drugs 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 235000001014 amino acid Nutrition 0.000 description 10
- 239000000463 material Substances 0.000 description 10
- 239000006193 liquid solution Substances 0.000 description 9
- 108010088751 Albumins Proteins 0.000 description 7
- 102000009027 Albumins Human genes 0.000 description 7
- 238000005903 acid hydrolysis reaction Methods 0.000 description 7
- 230000015556 catabolic process Effects 0.000 description 6
- 230000002255 enzymatic effect Effects 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 239000004094 surface-active agent Substances 0.000 description 6
- 208000031737 Tissue Adhesions Diseases 0.000 description 5
- 238000004925 denaturation Methods 0.000 description 5
- 230000036425 denaturation Effects 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 238000001914 filtration Methods 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 3
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 3
- 239000004971 Cross linker Substances 0.000 description 3
- 239000008186 active pharmaceutical agent Substances 0.000 description 3
- 239000000853 adhesive Substances 0.000 description 3
- 230000001070 adhesive effect Effects 0.000 description 3
- 239000003114 blood coagulation factor Substances 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000004891 communication Methods 0.000 description 3
- 230000001010 compromised effect Effects 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 239000002874 hemostatic agent Substances 0.000 description 3
- 108010009004 proteose-peptone Proteins 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000000565 sealant Substances 0.000 description 3
- 150000003384 small molecules Chemical class 0.000 description 3
- 102000004506 Blood Proteins Human genes 0.000 description 2
- 108010017384 Blood Proteins Proteins 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 102000002322 Egg Proteins Human genes 0.000 description 2
- 108010000912 Egg Proteins Proteins 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 108010058643 Fungal Proteins Proteins 0.000 description 2
- 108010011756 Milk Proteins Proteins 0.000 description 2
- 102000014171 Milk Proteins Human genes 0.000 description 2
- 108010033276 Peptide Fragments Proteins 0.000 description 2
- 102000007079 Peptide Fragments Human genes 0.000 description 2
- 108010064851 Plant Proteins Proteins 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 230000006862 enzymatic digestion Effects 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 235000021239 milk protein Nutrition 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 235000021118 plant-derived protein Nutrition 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000003825 pressing Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000007065 protein hydrolysis Effects 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000017423 tissue regeneration Effects 0.000 description 2
- 108010016626 Dipeptides Proteins 0.000 description 1
- 208000005422 Foreign-Body reaction Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 230000002009 allergenic effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012669 compression test Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000000635 electron micrograph Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 230000009969 flowable effect Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 102000034238 globular proteins Human genes 0.000 description 1
- 108091005896 globular proteins Proteins 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000008258 liquid foam Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 210000004224 pleura Anatomy 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000001878 scanning electron micrograph Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000007655 standard test method Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 239000003106 tissue adhesive Substances 0.000 description 1
- 229940075469 tissue adhesives Drugs 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 238000009777 vacuum freeze-drying Methods 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
- A61K9/122—Foams; Dry foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
- A61K38/014—Hydrolysed proteins; Derivatives thereof from animals from connective tissue peptides, e.g. gelatin, collagen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/363—Fibrinogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4833—Thrombin (3.4.21.5)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0028—Polypeptides; Proteins; Degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0028—Polypeptides; Proteins; Degradation products thereof
- A61L26/0042—Fibrin; Fibrinogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0028—Polypeptides; Proteins; Degradation products thereof
- A61L26/0047—Specific proteins or polypeptides not covered by groups A61L26/0033 - A61L26/0042
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/0085—Porous materials, e.g. foams or sponges
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/04—Materials for stopping bleeding
Definitions
- the invention relates to the field of pharmaceutical foams, such as pharmaceutical foams comprising peptones prepared by enzymatic hydrolysis of proteins.
- a foam is a substance that is formed by dispersing a gas in a liquid, such that bubbles of the gas are trapped in the liquid, with thin films of liquid separating the regions of gas.
- Pure liquids comprising no dissolved particles do not foam, such that the addition of a surfactant is generally required in order to reduce the surface tension of the liquid, enabling mixing of the gas with the liquid to form a stable foam.
- surfactants are usually amphiphilic in nature (i.e. having both a hydrophilic group and a lipophilic group), with long hydrophobic chains.
- Foams prepared from full-length proteins, which act as surfactants, are known. Full-length proteins require denaturation in order to provide the required surfactant characteristics.
- an amphiphilic agent is required i.e. a molecule which has both a hydrophilic group and a hydrophilic group, allowing the strands of denatured proteins to form micelles, within which gas, such as air, is trapped. This characteristic allows forming bubbles of air which are stable within the liquid.
- Foams are widely used in industry, such as in the food industry or as fire extinguishing foams. Foams are potentially useful in a wide variety of medical and surgical procedures, e.g. for providing protection of a surface, delivery of a drug, or to serve as a barrier for numerous surgical procedures. Use of a liquid foam enables fast and efficient coverage of a large area with a minimal amount of liquid.
- the strength of a foam may be expressed as the force required for the compression of the foam (i.e. compression strength), which may be measured using a device such as manufactured by Instron or Lloyd, using a method similar to that performed for the determination of the gelatin gel strength, the Bloom number.
- compression strength the force required for the compression of the foam
- Bloom number is a measure of the force (weight in grams) required to compress a given sample area a distance of 4 mm. A higher Bloom number indicates a stronger gel. Bloom number is proportional to the average molecular mass.
- a low Bloom number correlates to an average molecular mass of 20,000-25,000; a medium Bloom number (175-225) correlates to an average molecular mass of 40,000- 50,000; while a high Bloom number (225-325) correlates to an average molecular mass of 50,000-100,000.
- the invention in some aspects thereof, relates to a pharmaceutical (i.e. for medical and/or surgical use) foam composition
- a pharmaceutical i.e. for medical and/or surgical use
- foam composition comprising a peptone prepared by enzymatic hydrolysis of a full-length protein, wherein the foam is free of the full- length protein.
- peptones comprising short peptide lengths (e.g. of 90 or fewer amino acids)
- short peptide lengths e.g. of 90 or fewer amino acids
- peptones may be prepared from full-length proteins derived from different sources (e.g. gelatin, casein or protein mixtures) to obtain peptide fragments.
- Peptide fragments are short chains of amino acid monomers linked by amide bonds.
- Peptones may be obtained by different methods, such as by enzymatic, acidic, and/or alkali hydrolysis of full-length proteins.
- the shortest peptides can be dipeptides, consisting of two amino acids joined by a single peptide bond.
- Peptones used in the present invention are water-soluble mixtures comprising peptides and optionally free amino acids, formed by enzymatic hydrolysis/digestion of a full-length protein. In some embodiments, the peptones are devoid of free amino acids.
- a pharmaceutical foam composition comprising a peptone prepared by hydrolysis of a full-length protein, wherein the foam is free of the full-length protein.
- a pharmaceutical foam composition comprising a peptone prepared by enzymatic hydrolysis of a full-length protein, wherein the foam is free of said full-length protein.
- a pharmaceutical foam composition comprising a peptone prepared by enzymatic- digestion of a full length protein, wherein the foam is free of the full-length protein.
- a pharmaceutical foam composition comprising a protein hydrolysate prepared by enzymatic hydrolysis of a full-length protein, wherein said foam is free of the full- length protein.
- hydrolysate refers to a material produced by hydrolysis.
- hydrolysis usually means the cleavage of chemical bonds by the addition of water.
- protein hydrolysis relates to the breakdown of protein into smaller peptides and free amino acids.
- protein hydrolysis relates to the breakdown of protein by hydrolysis of the peptide bonds.
- protein hydrolysate refers to a product of hydrolysis of a protein that typically comprises peptides and free amino acids.
- the peptone or the protein hydrolysate comprises enzymatically-digested protein or enzymatically-hydrolyzed protein.
- the peptone, the protein hydrolysate, or the enzymatically- hydrolyzed protein is devoid of peptides of size greater than 11.7 kDa.
- the peptone, the protein hydrolysate or the enzymatically-hydrolyzed protein comprises peptides of size less than 10.0 kDa.
- peptones, protein hydrolysates or enzymatically- hydrolyzed proteins consist mainly of chain lengths below 10.0 kDa (of approximately 90 or fewer amino acids), such as, for example, from about 1000 Da up to about 10 kDa, from about 300 Da to about 500 Da, or even below 300 Da.
- the peptone, protein hydrolysate or enzymatically- hydrolyzed protein comprises peptides that are long, continuous, and unbranched peptide chains.
- the peptone, protein hydrolysate or enzymatically- hydrolyzed protein comprises peptides of approximately 90 or fewer amino acids.
- the full-length protein being hydrolyzed is a combination of two or more types of full-length proteins.
- the full-length protein being hydrolyzed is a single type of full-length protein.
- the full-length protein being hydrolyzed is selected from the group consisting of a milk protein (such as casein), a collagen-derived protein (such as gelatin), an egg protein, a blood protein (such as albumin), a yeast protein, a plant protein, or combinations thereof.
- the full-length protein being hydrolyzed is selected from the group consisting of casein and gelatin.
- the foam is stable.
- the enzymatic hydrolysis comprises use of a protease selected from the group consisting of a serine protease, a cysteine protease, a threonine protease, an aspartic protease, a glutamic protease, a metalloprotease and a combination thereof.
- a protease selected from the group consisting of a serine protease, a cysteine protease, a threonine protease, an aspartic protease, a glutamic protease, a metalloprotease and a combination thereof.
- the peptone, protein hydrolysate or enzymatically- hydrolyzed protein is present in the foam at a concentration of higher than about 0.05 to lower than about 20% w/v of the foam, such as, for example, at a concentration of higher than about 1.5 to lower than about 18.0 % w/v of the foam, or at a concentration of higher than about 1.66 to lower than about 17.86% w/v of the foam.
- the pharmaceutical foam composition further comprises fibrin and/or fibrinogen, optionally at a concentration in the range of from about 0.1 mg mL to about 10 mg/mL of the foam, such as, for example, at a concentration in the range of from about 2.3 mg/mL to about 7 mg/mL of the foam.
- the pharmaceutical foam composition further comprises thrombin, optionally at a concentration in the range of from about 0.1 IU/mL to about 100 IU/mL of the foam.
- a method for preparing a pharmaceutical foam composition comprising a step of: foaming a solution of a peptone, peptide hydrolysate or enzymatically-hydrolyzed protein with a gas, the solution of a peptone, peptide hydrolysate or enzymatically-hydrolyzed protein is prepared by enzymatic hydrolysis of a full-length protein in an aqueous solution, wherein the solution of a peptone, peptide hydrolysate or enzymatically- hydrolyzed protein is free of the full-length protein.
- a method for preparing a pharmaceutical foam composition comprising a step of: foaming a liquid solution of a peptone, peptide hydrolysate or enzymatically-hydrolyzed protein with a gas, the liquid solution of a peptone or a peptide hydrolysate is prepared by enzymatic hydrolysis of a full-length protein in a liquid, aqueous solution, wherein the solution of a peptone, peptide hydrolysate or enzymatically-hyrolyzed protein is free of the full-length protein.
- foaming refers to the process of preparing a foam by mixing a liquid solution with a gas. Foaming may be achieved manually or automatically. For example, foaming may be achieved by providing two containers (such as two syringes) in fluid communication one with the other, wherein a liquid solution is present in a first of the two containers and a gas, such as air, is present in the second of the two containers; passing the liquid from the first syringe into the gas in the second syringe or the gas from the second syringe into the liquid from the first syringe; then passing the liquid and gas between the two syringes until a foam is achieved.
- two containers such as two syringes
- a gas such as air
- foaming may be achieved by providing two containers (such as two syringes) in fluid communication one with the other, wherein a liquid for reconstitution is present in a first of the two containers and a gas, such as air, together with a peptone powder or protein hydrolysate is present in the second of the two containers; passing the liquid from the first syringe into the gas in the second syringe or the gas from the second syringe into the liquid from the first syringe; then passing the liquid and gas between the two syringes until a foam is achieved.
- two containers such as two syringes
- a liquid solution may be provided in a sealed container which does not have fluid communication with a gas until an operating mechanism is activated to bring the gas into contact with the liquid.
- a mechanism may include, for example, a pump device or a mechanism for breaking a seal of the sealed container.
- the passing of the liquid between the two syringes is performed at least 6 times.
- aqueous solution refers to a solution comprising water and at least one solute dissolved therein. In one embodiment, the term is intended to exclude emulsions or solutions comprising an oil.
- An emulsion is a mixture of two or more liquids that are normally immiscible
- a “liquid” is, for example, a fluid that conforms to the shape of its container but retains a (nearly) constant volume independent of pressure, and/or a flowable material.
- the peptone or peptide hydrolysate comprises enzymatically-digested protein.
- a method for preparing a pharmaceutical foam composition comprising a step of: foaming a solution of an enzymatically-digested protein with a gas, the solution of a an enzymatically-digested protein prepared by enzymatic hydrolysis of a full-length protein in an aqueous solution, wherein the solution of an enzymatically-digested protein is free of the full-length protein.
- a method for preparing a pharmaceutical foam composition comprising a step of: foaming a solution of an enzymatically-digested protein with a gas, the solution of a an enzymatically-digested protein prepared by enzymatic hydrolysis of a full-length protein in a liquid aqueous solution, wherein the liquid solution of an enzymatically- digested protein is free of the full-length protein.
- the peptone, the peptide hydrolysate or the enzymatically-digested protein comprises peptides of size less than 10.0 kDa.
- the peptone, the peptide hydrolysate or the enzymatically-digested protein comprises peptides of at least 1000 Da.
- the peptone, the protein hydrolysate or the enzymatically-digested protein comprises peptides having a size in the range of from 1000 Da to less than 10.0 kDa.
- the solution of a peptone, protein hydrolysate or enzymatically-digested protein is dried and prior to preparation, is reconstituted with a solution comprising water.
- the enzyme hydrolyses the full-length protein to produce a peptone, protein hydrolysate or enzymatically-hydrolyzed protein including peptides of size less than 10.0 kDa.
- the method further comprises, prior to foaming, removing peptides of size greater than 11.7 kDa from the solution of a peptone, protein hydrolysate or enzymatically-hydrolyzed protein. In some embodiments, the method further comprises, prior to foaming, removing peptides of size greater than 10 kDa from the solution of a peptone, protein hydrolysate or enzymatically-hydrolyzed protein.
- removing peptides of a selected size is performed by filtration, e.g. passage through a size exclusion membrane e.g. in a centrifugal filtration device.
- the full-length protein being hydrolyzed is a combination of proteins, such as 2, 3 or more different full-length proteins.
- the full-length protein being hydrolyzed is a single type of protein.
- the full-length protein being hydrolyzed is casein.
- the full-length protein being hydrolyzed is gelatin.
- enzymatic hydrolysis is carried out with a protease selected from the group consisting of a serine protease, a cysteine protease, a threonine protease, an aspartic protease, a glutamic protease, a metalloprotease and a combination thereof as long as the produced protein hydrolysate or peptone comprises peptides having a size in the range of from 1000 Da to less than 10.0 kDa and/or as long as the foaming ability of the peptone, protein hydrolysate or enzymatically- hydrolyzed protein is not compromised.
- a protease selected from the group consisting of a serine protease, a cysteine protease, a threonine protease, an aspartic protease, a glutamic protease, a metalloprotease and a combination thereof as long as the produced protein hydrolysate or peptone comprises peptide
- Solutions comprising peptone, protein hydrolysate or enzymatically- hydrolyzed protein at a concentration of less than about 50% w/v of the solution are considered to be beneficial for use in preparing the foam as disclosed herein.
- the peptone, protein hydrolysate or enzymatically-hydrolyzed protein is present at a concentration of lower than about 50 w/v of the solution e.g. at a concentration of higher than about 1 to lower than 50% w/v.
- the peptone, protein hydrolysate or enzymatically- hydrolyzed protein is present in the solution at a concentration of higher than about 1 to lower than about 40% w/v, such as, for example, at a concentration of higher than about 5 to lower than about 25% w/v.
- the method further comprises inactivating the enzyme upon completion of the hydrolysis.
- Enzyme inactivation can be carried out by altering the conditions required for enzymatic activity such as heating and/or pH adjustment, or by removing the enzyme (e.g. by affinity chromatography, size exclusion etc.) as long as the foaming ability of the peptone, protein hydrolysate or enzymatically- hydrolyzed protein is not compromised.
- the peptone, protein hydrolysate or enzymatically- hydrolyzed protein and/or the foam are free of an active enzyme used to prepare the peptone, protein hydrolysate or enzymatically-hydrolyzed protein.
- the method further comprises adding fibrinogen to the solution of a peptone, protein hydrolysate or enzymatically-hydrolyzed protein prior to foaming and after enzyme inactivation, optionally at a concentration in the range of from 1% w/v to up to about 30% w/v of the solution of a peptone, protein hydrolysate or enzymatically-hydrolyzed protein as long as the foaming ability of the peptone, protein hydrolysate or enzymatically-hydrolyzed protein is not compromised.
- the method further comprises adding thrombin to the pharmaceutical foam composition, optionally at a concentration of from about 0.1 IU/mL to about 100 IU/mL of the pharmaceutical foam composition. In one embodiment, the thrombin is added after foaming.
- a pharmaceutical foam obtained according to any of the methods disclosed herein.
- kits comprising a container comprising a peptone, protein hydrolysate or enzymatically-hydrolyzed protein, a device for obtaining a foam and optionally, a full-length protein other than the one subjected to hydrolysis.
- the full-length protein other than the one subjected to hydrolysis is fibrinogen.
- the kit further comprises a container comprising thrombin.
- the peptone, protein hydrolysate or enzymatically-hydrolyzed protein comprises peptides of size less than 10.0 kDa.
- the invention provides a pharmaceutical foam composition
- a pharmaceutical foam composition comprising a peptone, protein hydrolysate or enzymatically-hydrolyzed protein prepared by enzymatic hydrolysis of a full-length protein, wherein said foam is free of the full-length protein subjected to hydrolysis.
- the foam as disclosed herein is sturdier and more durable than foams known in the art, having greater tensile strength, determined by its increased resistance to compression.
- High strength and durability is important for applications in which the presence of the foam is required over an extended period, such as for wound healing, for sealing procedures or for adhesion prevention. In some situations, hemostasis must be ensured over an extended period of time, for example in patients medicated with anticoagulant drugs.
- the foam is required to have a high strength in order to withstand the stress resulting from specific applications, such as air sealing following lung surgery.
- the durability of the foam is important in order to provide a sturdy physical barrier between different organs at the surgical site.
- a matrix e.g. foam in which the cells can grow will remain durable throughout the initial healing phase.
- the foam as disclosed herein has reduced immunogenicity and/or reduced allergenic properties as compared to foams known in the art, allowing for repeated application.
- the foam as disclosed herein has greater adhesiveness than foams known in the art, which is highly advantageous in certain medical applications to allow the material to remain in position at the site of application.
- the foam as disclosed herein has a mean adhesion force to tissue of greater than 1 N/inch 2 , such as, for example at least 1 N/inch 2 , at least 2 N/inch 2 , at least 3 N/inch 2 , at least 4 N/inch 2 , at least 5 N/inch 2 , or even at least 6 N/inch 2 .
- the mean adhesion force to tissue is in the range of from about 1 N/inch 2 to about 6 N/inch 2 .
- the foam as disclosed herein has greater stiffness than foams known in the art, which is highly advantageous in certain medical applications i.e. for application to tissues where the foam must have strong cohesion to seal fluid or air leaks, especially where pressures may be elevated.
- the foam as disclosed herein has a mean stiffness of at least 3 N/mm, such as, for example, 3 N/mm, 4 N/mm, at least 5 N/mm at least 6 N/mm, at least 7 N/mm, at least 8 N/mm, at least 9 N/mm, at least 10 N.mm, at least 11 N/mm, at least 12 N/mm, at least 13 N/mm, at least 14 N/mm, at least 15 N/mm, at least 16 N/mm, at least 17 N/mm, or even at least 18 N/mm.
- the mean stiffness is in the range of from about 3 N/mm to about 19 N/mm. Additionally, in some embodiments, the foam must be able to remain intact, if the underlying tissue is expanding or contracting.
- the foam is stable, is not transient, and e.g. maintains its foam structure including height, volume, and/or porosity/mean pore size, for at least one hour after formation.
- the term "stable" with regard to a foam relates to a foam that can substantially support its own structure without collapse at a specified temperature.
- foam which is stable in vitro at physiological temperature retains at least 80% (such as 90%, 95% or higher) of its original structure including height, volume, and/or porosity/mean pore size for at least 1 hour at ambient temperature.
- collapse is most evidently characterized by the loss of foam structure after foam formation. Collapse usually results in a structure whose volume is significantly smaller than the volume of the original prepared foam.
- the foam as disclosed herein has a faster in-vivo degradation time than foams known in the art. Since peptones are already partially degraded proteins, these can be completely degraded more rapidly than native, intact/folded proteins. This property may reduce one or more of inflammatory reaction, foreign body reaction and post-surgical adhesions.
- degradation time means the time required for at least 90% of the peptone components of the foam to be degraded in-vivo.
- the desired degradation time of the foam is dependent on the intended use (e.g. as sealant or hemostat), tissue type, amount used, chance of re-bleeding or re- leaking, pressures involved, patient condition, etc.
- a sealant or hemostat be present long enough to allow for tissue repair, but to not impede tissue repair.
- a foam for use as a sealant or hemostat has a longevity of 4-5 days.
- the foam as disclosed herein is free of a non-protein surfactant.
- the foam as disclosed herein is prepared in the absence of a non-protein surfactant.
- the peptone, protein hydrolysate or enzymatically- hydrolyzed protein used to prepare the foam has not being subjected to denaturation prior to foaming.
- the peptone is not denatured.
- the full-length protein subjected to hydrolysis, to prepare the peptone the protein hydrolysate or enzymatically-hydrolyzed protein has not been subjected to denaturation prior to foaming.
- the solution of a peptone, protein hydrolysate or enzymatically-hydrolyzed protein is free from denatured proteins.
- the solution of a peptone, peptide hydrolysate or enzymatically-hydrolyzed protein is free from denatured proteins other than the hydrolyzing enzyme(s).
- the solution of a peptone, peptide hydrolysate or enzymatically-hydrolyzed protein includes other full-length protein, wherein the other full length protein is one that was not subjected to the enzymatic hydrolysis
- the other full length protein is present in the peptone, protein hydrolysate or enzymatically-hydrolyzed protein in addition to the hydrolyzing enzyme, and the other full-length protein has not been subjected to denaturation prior to foaming.
- denaturation is a process of modifying the secondary and/or tertiary molecular structure of a protein/peptide e.g. by heating, by treatment with alkali, acid, urea, or detergent.
- alkali, acid, urea, or detergent When a protein is denatured, secondary and/or tertiary structures are altered but the peptide bonds of the primary structure between the amino acids are left intact.
- enzymatic hydrolysis means a full-length protein is enzymatically hydrolyzed to a point at which the peptone solution is free of the original full-length protein.
- enzymatic hydrolysis according to the invention also includes hydrolyzation to a point in which a given enzyme did not hydrolyze/digest all possible digestion sites of the full length protein that are recognized by the enzyme.
- the pharmaceutical foam composition disclosed herein is substantially devoid and/or substantially free of the full-length protein that was subjected to enzymatic hydrolysis.
- the term “substantially free” or “substantially devoid of with regard to the full-length protein means that the composition contains less than 5 w/v %, less than 4 w/v %, less than 3 w/v %, less than 2 w/v %, less than 1 w/v %, less than 0.5 w/v %, less than 0.1 w/v % or less than 0.05 w/v% of the full-length protein.
- the term “solution of a peptone” refers to a solution, such as a liquid solution, comprising a peptone and optionally other components, such as small molecules, salts, active pharmaceutical ingredients, and coagulation factors.
- solution of a peptide hydrolysate refers to a solution, such as a liquid solution, comprising the peptide hydrolysate and optionally other components, such as small molecules, salts, active pharmaceutical ingredients, and coagulation factors.
- solution of an enzymatically-hydrolyzed protein refers to a solution, such as a liquid solution, comprising the enzymatically- hydrolyzed protein and optionally other components, such as small molecules, salts, active pharmaceutical ingredients, and coagulation factors.
- the peptone is derived from a milk protein (such as casein), a collagen-derived protein (such as gelatin, e.g., prepared from skin, cartilage or bones), an egg protein, a blood protein (such as albumin), a yeast protein, a plant protein, or combinations thereof.
- a milk protein such as casein
- a collagen-derived protein such as gelatin, e.g., prepared from skin, cartilage or bones
- an egg protein such as albumin
- a blood protein such as albumin
- yeast protein such as a yeast protein, a plant protein, or combinations thereof.
- the resulting peptone solution may also include fats, metals, salts, vitamins and many other biological compounds.
- the invention provides a kit comprising a container comprising a protein hydrolysate prepared by enzymatic hydrolysis of a full-length protein, a device for foaming the hydrolysate and optionally, a full-length protein other than that subjected to the enzymatic hydrolysis.
- the invention provides a method for preparing a pharmaceutical foam composition, comprising a step of: foaming a solution of a protein hydrolysate with a gas, the solution of the protein hydrolysate prepared by enzymatic hydrolysis of a full-length protein in an aqueous solution, wherein said solution is free of said full-length protein.
- the invention provides a method for preparing a pharmaceutical foam composition comprising: enzymatically hydrolyzing a full-length protein in an aqueous solution until said solution is free of said full- length protein thereby obtaining a solution of a peptone or protein hydrolysate; and foaming said solution of said peptone or protein hydrolysate with a gas.
- the invention provides a pharmaceutical foam composition obtained according to the method of the invention.
- a peptone- based foam prepared by hydrolysis of a full-length protein, wherein the foam is free of the full-length protein that was subjected to hydrolysis.
- peptone based foam means that the majority of the foam (more than half of the total weight of the foam) is composed of peptone.
- foam e.g. proteins other than the full-length protein that was subjected to hydrolysis can be present.
- the foam can comprise 1% to 100% peptone out of the total dissolved components.
- Proteins other than the full-length protein that was subjected to hydrolysis can be present in the foam in at concentrations of up to or equal to 49% while the remaining components consist of peptone.
- full-length protein refers to a protein prior to hydrolysis/digestion.
- the ratio of air to liquid used in preparing the foam was in the range of from 1:3 to 3:1 ainliquid. In some preferred embodiments, the ratio of air to liquid is in the range of from about 2:1 to about 3:1 ainliquid.
- Protein molecules are often very large and are made up of hundreds to thousands of amino acid units. Proteins include naturally occurring proteins or fragments thereof and/or synthetic proteins.
- the foam can be dried or non-dried.
- a dry foam can be obtained by reducing the concentration of water e.g. by air drying, vacuum drying, or freeze drying.
- dry foam refers to foam comprising water content of equal to or less than 3% by weight based on the total weight of the foam composition (w/w).
- a method for promoting blood coagulation; sealing; prevention and/or reduction of adhesion; and/or wound healing comprising application of a pharmaceutical foam composition according to the invention.
- FIG. 1 is a bar graph showing the tensile strength of foams prepared from full- length gelatin and full-length Bovine Serum Albumin (BSA), or from peptone obtained by enzymatic hydrolysis of full-length gelatin;
- BSA Bovine Serum Albumin
- FIG. 2 is a bar graph showing the tensile strengths of foams prepared from full-length BSA, casein or gelatin and from peptone obtained by enzymatic or acid hydrolysis of the full-length casein or gelatin;
- FIG. 3 is a bar graph showing the effect of peptone concentration on tensile strength for peptone obtained by enzymatic hydrolysis of full-length gelatin;
- FIG. 4 is a bar graph showing the effect of BAC2 concentration on tensile strength for peptone obtained by enzymatic hydrolysis of full-length gelatin;
- FIG. 5 is a bar graph showing the tensile strength of foams prepared from full- length gelatin and from peptone derived from enzymatic hydrolysis of full-length gelatin in the presence and absence of fibrinogen;
- FIG. 6 is a dot graph showing tissue adhesion strength of foams prepared from peptones obtained by enzymatic hydrolysis of full-length gelatin or casein, as compared to foams prepared from full-length albumin;
- FIG. 7 is a dot graph showing stiffness of foams prepared from peptones obtained by enzymatic hydrolysis of full-length gelatin or casein, as compared to foams prepared from full-length albumin;
- FIG. 8 shows scanning electron micrographs for foams prepared from full- length gelatin (8A) and from foam prepared from peptone obtained by enzymatic hydrolysis of full-length gelatin (8B);
- FIG. 9 shows the effect of peptone peptide size on tensile strength of foams prepared from full-length gelatin, from peptone derived from enzymatic hydrolysis of full-length gelatin and from peptone derived from enzymatic hydrolysis of full-length gelatin having peptides of less than about 10 kDa;
- FIG. 10 shows the effect of mixing peptones obtained by enzymatic hydrolysis of full-length gelatin with full-length gelatin on the tensile strength of the foam.
- the invention in some embodiments thereof, relates to a pharmaceutical foam composition
- a pharmaceutical foam composition comprising peptone prepared by enzymatic hydrolysis of protein(s).
- foams obtained from peptones have increased adhesive characteristics as compared to foams obtained from full-length proteins.
- cross-linker was not required to obtain sturdy foam from peptones, but can be optionally be added.
- peptones comprising peptides of equal to or less than 10 kDa provided sturdier foams than full-length proteins.
- Thrombin (Thrombin component of EVICEL®, cats#3901,3902, 3905,
- Example 1 Tensile strength of foams prepared from peptone and from full-length BSA and gelatin.
- Foam comprising full-length gelatin, fibrinogen source (BAC2) and thrombin;
- Foam comprising BSA, fibrinogen source (BAC2) and thrombin;
- Foam comprising peptone obtained by enzymatic hydrolysis of full-length gelatin, fibrinogen source (BAC2) and thrombin; and
- Control foam comprising fibrinogen source (BAC2) and thrombin.
- a 5% w/v aqueous solution of each of full-length gelatin, full-length BSA and peptone obtained by enzymatic hydrolysis of full-length gelatin was prepared (foam nos. 1-3 from left to right).
- 500 iL of a concentrated BAC2 solution were added to provide a final concentration of 10 % BAC2, comprising in total about 35 mg fibrinogen.
- the solutions were foamed by using two syringes, interconnected with a 2 cm Tyvec tubing ( ⁇ 2 mm diameter).
- the solutions as prepared above were drawn into the first syringe, and 10 mL of air were drawn into the second syringe.
- the solutions were expelled back and forth between the first and second syringes, thereby admixing the solution with the air.
- Example 2 Tensile strength of foams prepared from peptone obtained by enzymatic or acid hydrolysis of selected full-length proteins.
- a 5% w/v aqueous solution of each of full-length gelatin, BSA and casein; peptone obtained by enzymatic or acidic hydrolysis of casein; and peptone obtained by enzymatic hydrolysis of gelatin was prepared.
- Foam was prepared in two 50 mL syringes. The first syringe was loaded with 20 mL of a 5% protein solution and 2 mL BAC2. In the second syringe 40 mL air were loaded. Following foaming by vigorous admixing of the air into the liquid the prepared material was expelled into a cup with a diameter of 60 mm, at a height of 20 mm.
- the force required for compression was evaluated at 0.5 mm/sec for a depth of 4 mm. Foams prepared from full-length gelatin and peptones were tested in triplicate, foams prepared from full-length BSA and casein were tested in duplicate.
- a 50% w/v aqueous solution of peptone obtained by enzymatic hydrolysis of full-length gelatin was prepared by dissolving 50 g peptone powder in 100 mL water. The solution was diluted with water to obtain 1%, 5%, 10%, and 25% aqueous solutions of peptone.
- Example 4 Effect of BAC2 concentration on tensile strength of foam.
- a 5% aqueous solution of peptone obtained by enzymatic hydrolysis of gelatin was prepared.
- BAC2 At the final step of the preparation, BAC2, at concentration of 1%, 5%, 10% or 30% w/v was added, wherein each percent of BAC2 comprised about 7 mg fibrinogen.
- The, final foam was prepared and tested in quadruplicates as described in Example 3. Results are presented in Figure 4.
- Example 5 Tensile strength of foams prepared from peptone and from gelatin in the presence and absence of fibrinogen.
- Foams were prepared substantially as described in Example 1, except that foams comprising about 35 mg fibrinogen and 20 IU thrombin, as well as foams devoid of BAC2 were prepared. Triplicates of the samples were tested.
- Aqueous solutions were prepared as follows:
- Foams were prepared from 5 mL of each solution, substantially as described above for Example 1, except that the amount of BAC2 added to each foam was identical, and the amount of thrombin was adjusted to achieve a comparable fibrinogen polymerization rate. Five replicates were tested for each formulation. The liquid: air ratio for each foam preparation was 1 : 3, providing a homogeneous foam, without large air pockets or bubbles.
- tissue adhesion was greater with foams prepared from gelatin peptone or casein peptone as compared to intact albumin.
- Foams prepared from casein peptone had the highest maximum adhesion and stiffness.
- Mean maximum adhesion scores were as follows: intact albumin 0.97 N; gelatin peptone 1.19 N; and casein peptone 1.58 N.
- the failure mode was adhesive, i.e. failure occurred at the tissue: foam interface, and not cohesive i.e. failure did not occur within the test article.
- Example 7 Scanning Electron Microscope (SEM) studies.
- Foams were prepared from aqueous solutions of 5% w/v full-length gelatin and 5% w/v peptone obtained by enzymatic hydrolysis of full-length gelatin, with the addition of BAC2 and thrombin, as described above for Example 1. ⁇ ⁇
- Figures 8A and 8B show electron micrographs for foams prepared from full- length gelatin (8A) and from foam prepared from peptone obtained by enzymatic hydrolysis of gelatin (8B).
- foams prepared from peptone had higher density and smaller air pockets than foam prepared from full-length protein. It is expected that the foam prepared from gelatin would be less stable due to the large bubble structure, while the foam obtained from the peptone would be more stable and more rigid. It is hypothesized that the differences may be due to the greater hydrophobicity of the full-length protein.
- Example 8 Effect of peptide size on tensile strength.
- aqueous solutions of 5% w/v full-length gelatin and 5% w/v of peptone obtained by enzymatic hydrolysis of full-length gelatin were prepared.
- Foams were prepared from 5 mL of each of the full-length gelatin solution, and of the solutions comprising peptone, with and without filtration centrifugation , as described in Example 1. Force required for compression of the foams was tested in quadruplicates as described in Example 1. Results are presented in Figure 9.
- foam prepared from a solution of peptone comprising only peptides of length less than 10 kDa required greater force for compression.
- Samples comprising a mixture of full-length gelatin and peptone, in ratios of gelatin: peptone 40:60 and 95:5 were also prepared.
- Foams were prepared from 5 mL of each of full-length gelatin, peptone alone, and gelatin: peptone mixtures at each of the two ratios, as described in Example 1. Force required for compression of each foam was tested in quadruplicates as described in Example 1. Results are presented in Figure 10.
- foams prepared from solutions comprising an admixture of full-length gelatin with peptone obtained by enzymatic hydrolysis of full-length gelatin required less force for compression than foams comprising either full-length gelatin or peptone alone.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Materials Engineering (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Dispersion Chemistry (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Materials For Medical Uses (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019536003A JP7114597B2 (ja) | 2016-09-14 | 2017-09-11 | 安定な医薬フォーム |
EP17780529.8A EP3512502A1 (en) | 2016-09-14 | 2017-09-11 | Stable pharmaceutical foam |
AU2017328480A AU2017328480A1 (en) | 2016-09-14 | 2017-09-11 | Stable pharmaceutical foam |
CN201780056569.1A CN109789091A (zh) | 2016-09-14 | 2017-09-11 | 稳定的药物泡沫 |
CA3036770A CA3036770A1 (en) | 2016-09-14 | 2017-09-11 | Stable pharmaceutical foam |
KR1020197010499A KR102656742B1 (ko) | 2016-09-14 | 2017-09-11 | 안정한 약제학적 폼 |
IL265252A IL265252B2 (en) | 2016-09-14 | 2017-09-11 | Stable pharmaceutical foam |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662394371P | 2016-09-14 | 2016-09-14 | |
US62/394,371 | 2016-09-14 | ||
IL247810A IL247810A0 (en) | 2016-09-14 | 2016-09-14 | Stable pharmaceutical foam |
IL247810 | 2016-09-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2018051325A1 true WO2018051325A1 (en) | 2018-03-22 |
Family
ID=60022140
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IL2017/000007 WO2018051325A1 (en) | 2016-09-14 | 2017-09-11 | Stable pharmaceutical foam |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP3512502A1 (ko) |
JP (1) | JP7114597B2 (ko) |
KR (1) | KR102656742B1 (ko) |
CN (1) | CN109789091A (ko) |
AU (1) | AU2017328480A1 (ko) |
CA (1) | CA3036770A1 (ko) |
IL (1) | IL265252B2 (ko) |
MA (1) | MA46239A (ko) |
WO (1) | WO2018051325A1 (ko) |
Citations (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2492458A (en) | 1944-12-08 | 1949-12-27 | Jr Edgar A Bering | Fibrin foam |
US6454787B1 (en) | 1998-12-11 | 2002-09-24 | C. R. Bard, Inc. | Collagen hemostatic foam |
EP1257304A1 (en) | 2000-02-25 | 2002-11-20 | Monterey Biomedical, Inc. | Foam-forming wound dressing |
US20030138391A1 (en) * | 2002-01-24 | 2003-07-24 | Midwest Grain Products | Liquid foam builder containing hydrolyzed grain protein |
US6730299B1 (en) | 1999-07-21 | 2004-05-04 | Imedex Biomateriaux | Adhesive protein foam for surgical and/or therapeutic uses |
WO2009083544A2 (en) * | 2007-12-28 | 2009-07-09 | Kuros Biosurgery Ag | Pdgf fusion proteins incorporated into fibrin foams |
WO2009144091A2 (en) * | 2008-04-18 | 2009-12-03 | N.V. Organon | Purification of protein hydrolysate and the resultant products |
WO2010088469A2 (en) | 2009-01-30 | 2010-08-05 | Ethicon, Inc. | Collagen-related peptides and uses thereof and hemostatic foam substrates |
US8512740B2 (en) | 2008-03-26 | 2013-08-20 | Baxter International Inc. | Fibrin foam and process for making |
US8603543B2 (en) | 2007-08-14 | 2013-12-10 | The Regents Of The University Of California | Mesocellular oxide foams as hemostatic compositions and methods of use |
WO2014071053A2 (en) | 2012-11-01 | 2014-05-08 | Falus George D | Improvements on tissue sealant for use in non-compressible hemorrhage |
US8741335B2 (en) | 2002-06-14 | 2014-06-03 | Hemcon Medical Technologies, Inc. | Hemostatic compositions, assemblies, systems, and methods employing particulate hemostatic agents formed from hydrophilic polymer foam such as Chitosan |
WO2014086996A1 (en) | 2012-12-07 | 2014-06-12 | Baxter International Inc. | Hemostatic foam |
US8753670B2 (en) | 2008-03-26 | 2014-06-17 | Baxter International Inc. | Fibrin foam and process |
US8778883B2 (en) | 2009-11-13 | 2014-07-15 | Industrial Technology Research Institute | Foamy biomaterial for biological tissue repair |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH264752A (de) * | 1947-06-03 | 1949-10-31 | Hoffmann La Roche | Verfahren zur Herstellung von Trägern für Arzneimittel. |
JPS5814813B2 (ja) * | 1976-11-09 | 1983-03-22 | 味の素株式会社 | 起泡剤及びその製造法 |
CN1250605C (zh) * | 2001-03-26 | 2006-04-12 | 拜尔公司 | 具有显著剪切变稀行为的聚碳酸酯 |
EP2259803B2 (en) * | 2008-02-29 | 2019-03-13 | Ferrosan Medical Devices A/S | Device for promotion of hemostasis and/or wound healing |
EP2252335B1 (en) * | 2008-03-03 | 2013-04-24 | Omrix Biopharmaceuticals Ltd. | A gelatin sponge comprising an active ingredient, its preparation and use |
RU2013155713A (ru) | 2011-07-06 | 2015-08-20 | Профибрикс Бв | Составы для лечения ран |
CN105543315A (zh) * | 2015-12-16 | 2016-05-04 | 陕西科技大学 | 胶原蛋白类发泡剂、其复配改性发泡剂以及二者的制备方法 |
-
2017
- 2017-09-11 EP EP17780529.8A patent/EP3512502A1/en not_active Withdrawn
- 2017-09-11 AU AU2017328480A patent/AU2017328480A1/en not_active Abandoned
- 2017-09-11 WO PCT/IL2017/000007 patent/WO2018051325A1/en unknown
- 2017-09-11 CN CN201780056569.1A patent/CN109789091A/zh active Pending
- 2017-09-11 CA CA3036770A patent/CA3036770A1/en not_active Abandoned
- 2017-09-11 KR KR1020197010499A patent/KR102656742B1/ko active IP Right Grant
- 2017-09-11 MA MA046239A patent/MA46239A/fr unknown
- 2017-09-11 JP JP2019536003A patent/JP7114597B2/ja active Active
- 2017-09-11 IL IL265252A patent/IL265252B2/en unknown
Patent Citations (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2492458A (en) | 1944-12-08 | 1949-12-27 | Jr Edgar A Bering | Fibrin foam |
US6454787B1 (en) | 1998-12-11 | 2002-09-24 | C. R. Bard, Inc. | Collagen hemostatic foam |
US6730299B1 (en) | 1999-07-21 | 2004-05-04 | Imedex Biomateriaux | Adhesive protein foam for surgical and/or therapeutic uses |
EP1257304A1 (en) | 2000-02-25 | 2002-11-20 | Monterey Biomedical, Inc. | Foam-forming wound dressing |
US20030138391A1 (en) * | 2002-01-24 | 2003-07-24 | Midwest Grain Products | Liquid foam builder containing hydrolyzed grain protein |
US8741335B2 (en) | 2002-06-14 | 2014-06-03 | Hemcon Medical Technologies, Inc. | Hemostatic compositions, assemblies, systems, and methods employing particulate hemostatic agents formed from hydrophilic polymer foam such as Chitosan |
US8603543B2 (en) | 2007-08-14 | 2013-12-10 | The Regents Of The University Of California | Mesocellular oxide foams as hemostatic compositions and methods of use |
WO2009083544A2 (en) * | 2007-12-28 | 2009-07-09 | Kuros Biosurgery Ag | Pdgf fusion proteins incorporated into fibrin foams |
US8512740B2 (en) | 2008-03-26 | 2013-08-20 | Baxter International Inc. | Fibrin foam and process for making |
US8753670B2 (en) | 2008-03-26 | 2014-06-17 | Baxter International Inc. | Fibrin foam and process |
WO2009144091A2 (en) * | 2008-04-18 | 2009-12-03 | N.V. Organon | Purification of protein hydrolysate and the resultant products |
WO2010088469A2 (en) | 2009-01-30 | 2010-08-05 | Ethicon, Inc. | Collagen-related peptides and uses thereof and hemostatic foam substrates |
US8778883B2 (en) | 2009-11-13 | 2014-07-15 | Industrial Technology Research Institute | Foamy biomaterial for biological tissue repair |
WO2014071053A2 (en) | 2012-11-01 | 2014-05-08 | Falus George D | Improvements on tissue sealant for use in non-compressible hemorrhage |
WO2014086996A1 (en) | 2012-12-07 | 2014-06-12 | Baxter International Inc. | Hemostatic foam |
Non-Patent Citations (1)
Title |
---|
RAFAEL A GARCIA ET AL: "The non-nutritional performance characteristics of peptones made from rendered protein", JOURNAL OF INDUSTRIAL MICROBIOLOGY & BIOTECHNOLOGY ; OFFICIAL JOURNAL OF THE SOCIETY FOR INDUSTRIAL MICROBIOLOGY, SPRINGER, BERLIN, DE, vol. 37, no. 1, 3 November 2009 (2009-11-03), pages 95 - 102, XP019765112, ISSN: 1476-5535 * |
Also Published As
Publication number | Publication date |
---|---|
KR102656742B1 (ko) | 2024-04-15 |
CA3036770A1 (en) | 2018-03-22 |
JP2019526646A (ja) | 2019-09-19 |
IL265252B2 (en) | 2023-11-01 |
JP7114597B2 (ja) | 2022-08-08 |
IL265252B1 (en) | 2023-07-01 |
KR20190054110A (ko) | 2019-05-21 |
CN109789091A (zh) | 2019-05-21 |
AU2017328480A1 (en) | 2019-03-14 |
IL265252A (en) | 2019-05-30 |
EP3512502A1 (en) | 2019-07-24 |
MA46239A (fr) | 2019-07-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3463498B1 (en) | Plasma-based films and methods for making and using the same | |
Burke et al. | Thermal gelation and tissue adhesion of biomimetic hydrogels | |
AU2013353931B2 (en) | Hemostatic foam | |
US8257690B2 (en) | Protein-based polymer tissue adhesives for medical use | |
US20050037960A1 (en) | Methods and compositions for sealing tissue leaks | |
US20160375172A1 (en) | Flowable collagen-based hemostat and methods of use | |
CN110801528A (zh) | 一种硬脊膜封合水凝胶及其制备方法与应用 | |
EP3074055B1 (en) | Dry pad comprising thrombin and pectin | |
US11938165B2 (en) | Stable pharmaceutical foam | |
WO2018051325A1 (en) | Stable pharmaceutical foam | |
JP5889188B2 (ja) | 組織接着用シート製剤 | |
AU2016261108B2 (en) | Haemostatic compositions | |
CN110121350A (zh) | 包含阴离子交换剂和钙盐的止血组合物 | |
EP2556842A1 (en) | Composition in the form of film comprising fibrinogen and a fibrinogen activator and the applications thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17780529 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3036770 Country of ref document: CA Ref document number: 2019536003 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2017328480 Country of ref document: AU Date of ref document: 20170911 Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 20197010499 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2017780529 Country of ref document: EP Effective date: 20190415 |